Friday, July 25, 2014

XTL hopes to begin major lupus trial next year

XTL hopes to begin major lupus trial next year

July 22, 2014 by · Leave a Comment 

Tweet XTL Biopharmaceuticals (NASDAQ:XTLB; TASE:XTL) is aiming to begin a Phase 2b clinical trial in the first half of 2015 with its hCDR1 peptide to treat patients with systemic lupus erythematosus (SLE). “We are in the process of finalizing our trial design, approaching the FDA and hope to have feedback from the agency before the […]

Taking a ride across the BBB with biOasis

Taking a ride across the BBB with biOasis

July 15, 2014 by · Leave a Comment 

Tweet biOasis (OTCQX:BIOAF; TSX-V:BTI) believes its Transcend family of technologies holds the key to allow drug therapies to penetrate the blood-brain barrier (BBB) – long considered a Holy Grail of neurological medical research – to treat diseases of the central nervous system. “Our Transcend breakthrough is a naturally occurring physiological transport mechanism that can act […]

Medifocus readies marketing expansion of Prolieve

Medifocus readies marketing expansion of Prolieve

July 8, 2014 by · Leave a Comment 

http://www.youtube.com/watch?v=VeDTgeap28k’]

Tweet Medifocus (OTCQX:MDFZF; TSX-V:MFS) is raising $6-million to $10-million to expand the sales and marketing of its minimally invasive Prolieve device as a treatment for benign prostatic hyperplasia (BPH), or enlarged prostate, and to expand its use to include the treatment of prostatitis and prostate cancer. “Our current marketing plan for Prolieve is focused on […]

Response Biomedical charting turnaround story

Response Biomedical charting turnaround story

July 1, 2014 by · Leave a Comment 

Tweet The new management team of Response Biomedical (OTCBB:RPBIF; TSX:RBM), with the strong support of its controlling shareholder, OrbiMed Advisors, has adopted an aggressive plan to drive sales and achieve profitability. Jeff Purvin, who moved into the executive suite as CEO about two years ago, contends that any corporate turnaround needs more than tweaking the […]

Ciclofilin developing first drug for HCV/HIV-1 co-infection

Ciclofilin developing first drug for HCV/HIV-1 co-infection

June 24, 2014 by · Leave a Comment 

Tweet Closely held Ciclofilin Pharmaceuticals is developing what, it hopes, will be the first clinically effective treatment for hepatitis C virus (HCV)/HIV-1 co-infection, with specific antiviral activity directed against both viruses. “Other companies are working on one or the other virus, so we would like to position ourselves as the company working on co-infection, where […]

Trillium eyeing pre-IND meeting in third quarter

Trillium eyeing pre-IND meeting in third quarter

June 17, 2014 by · Leave a Comment 

Tweet Trillium Therapeutics (TSX:TR; OTCQX:SCTPF) hopes to have a pre-IND meeting with the FDA in the second half of this year and begin clinical testing of its lead biologic cancer immunotherapy, SIRPαFc, for the treatment of acute myeloid leukaemia (AML) in the second half of 2015. “There is strong evidence that AML is sustained by leukemia […]

Mati Therapeutics isn’t your traditional biotech startup

Mati Therapeutics isn’t your traditional biotech startup

June 10, 2014 by · Leave a Comment 

Tweet Not quite two years old yet, closely held Mati Therapeutics is conducting a pre-Phase 3 clinical trial with an ocular punctal plug delivery system (PPDS) that could become a preferred alternative to eye drops. “Because of the Phase 2 trials conducted by QLT on this technology, we have a different risk-reward profile than a […]

Opexa is personalizing the treatment of autoimmune disease

Opexa is personalizing the treatment of autoimmune disease

June 3, 2014 by · Leave a Comment 

Tweet With its Phase 2b clinical trial in secondary-progressive multiple sclerosis (SPMS) running nicely, Opexa Therapeutics (NASDAQ:OPXA) is considering adding a new disease indication to its antigen-specific T-cell immunotherapy platform. “We haven’t given guidance as to which disease we are targeting, but the number of potential T-cell mediated autoimmune diseases is numerous,” president and CEO, […]

Enrollment in Athersys stroke trial nears completion

Enrollment in Athersys stroke trial nears completion

May 27, 2014 by · Leave a Comment 

Tweet Athersys (NASDAQ:ATHX) expects to complete enrollment by the end of the summer in a Phase 2 clinical trial of its MultiStem cell therapy in about 140 moderate to moderately-severe ischemic stroke patients, with data to be released before year end. “If we get the results we’re looking for, this could have a dramatic impact […]

GeneNews’ IDL off to flying start

GeneNews’ IDL off to flying start

May 20, 2014 by · Leave a Comment 

Tweet GeneNews’ (TSX:GEN) recently formed U.S. joint venture, Innovative Diagnostic Laboratory (IDL), took a huge step forward in the first quarter in its goal of becoming a leader in molecular diagnostics and personalized medicine. “With a successful limited scale launch of IDL in the fourth quarter of 2013, full scale-up activities began in the first […]

Next Page »

Email Newsletters with Constant Contact
Google+